BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression

By WebmasterJune 27, 2016November 1st, 2024No Comments

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression

See more here

Previous PostMcKesson Health Solutions Extends VBR Portfolio with ClarityQx Value-Based Payment Technology
Next PostMelior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostMcKesson Health Solutions Extends VBR Portfolio with ClarityQx Value-Based Payment Technology

Next PostMelior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study